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Pulmonary Vascular Disease
MILTONPACKER, MD, FACC, NORMA MEDINA, RN,MADELINEYUSHAK, RN
New York, New York
The hemodynamic and clinical responses to calcium
channel blockade with verapamil and nifedipine were
compared with those of hydralazine in12 patients with
pulmonary hypertension secondary to obliterative pul-
monary vascular disease. All three drugs produced a
marked and similar decrease in pulmonary vascular re-
sistance; however, this was accompanied by a significant
increase in cardiac index with hydralazine(+ 0.71 li-
ter/min per m2, p < 0.01), no change in cardiac index
with nifedipine and a significant decrease in cardiac in-
dex with verapamil(- 0.25 liter/min per m2, p < 0.05).
Mean pulmonaryarterypressure decreased markedly
with both calcium channel blocking drugs(-16.0 mm
Hg with verapamil and-14.5 mm Hg with nifedipine,
both p< 0.01), but this was associated with a concom-
itant increase in mean right atrial pressure (+6.2 mm
Hg with verapamil and+4.4 mm Hg with nifedipine,
Over the last20 years, a number ofvasodilatordrugs have
been administeredto patients withpulmonaryhypertension
in the hope of producing hemodynamic and clinical im-
provement,but initial reports of benefit in selected patients
have been frequently followed by reports(1) of drug failure
and adverse reactions. Earlyexperience(2,3) suggested that
alpha-adrenergicantagonists, such as tolazoline and phen-
tolamine, lowered pulmonaryvascular resistance in patients
with pulmonaryhypertension,but further studies(4,5) in-
dicated that the responses to these drugs varied greatly and
some individuals experiencedadverse effects. Beta-adren-
ergic agonists, such as isoproterenol, reduced pulmonary
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both P< 0.01); neither variable changed after hydral-
azine. Hence, rightventricularperformance (as reflected
by right ventricular stroke work index)deteriorated dur-
ingtreatmentwith both calciumchannel blockingdrugs,
despite the decrease in resistance to right ventricular
ejection; in contrast, right ventricular stroke work index
increased after hydralazine. The unfavorable hemody-
namic effects of calcium channel blockade were accom-
panied by severe adverse clinical events, including pro-
found hypotension and cardiogenic shock during acute
drug administration and the exacerbation of right heart
failure during long-termtreatment.These deleterious
responses to verapamil and nifedipine are likely thereo
suit of a direct depressant effect exerted by these drugs
on right ventricular function independent of their pul-
monary vasodilatory actions.
artery pressures and increased cardiac output during short-
term therapy in a few patients(6), but tachycardiawas
frequent(6,7) andexacerbationsof pulmonaryhypertension
occasionally complicatedtreatment(8-10). Most recently,
direct-acting vasodilators, such as diazoxide and hydrala-
zine, produced dramatic benefits in small numbers of pa-
tients with pulmonaryhypertension(11-13), butsubsequent
reports (1,14,15) noted that long-term therapy was often
not clinically beneficial and even short-termtreatmentcould
result in severe adverse reactions.
The recent observations (16-19) that calcium channel
blockade with verapamil and nifedipine attenuates experi-
mentally induced hypoxicpulmonaryvasoconstrictionhas
raised new hope that these agents might prove useful in the
management of pulmonaryhypertensivestates in patients.
Clinical experience has confirmed that nifedipine produces
marked and immediate reductions inpulmonaryartery pres-
sures in hypoxemic patients with acuterespiratoryfailure
and with chronicobstructive pulmonarydisease (20-22).
These results haveencouragedthe use of calcium channel
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blockade in thetreatmentof patients with primary pulmo-
naryhypertensionand otherobliterativepulmonary vascular
diseases, and earlyexperience(23-31) with these agents in
these disorders has been favorable. In these reports(23-31),
nifedipine lowered pulmonaryvascularresistance and pul-
monary artery pressures at rest and during exercise during
short- andlong-termtreatment,and these effects were ac-
companiedby symptomaticimprovement(30). These find-
ings suggested that calcium might play a crucial role in
mediating thevasoconstrictionthat is thought to underlie
the pathogenesis of pulmonary hypertensive states
(2,18,32,33).
Our experience, however, is in contrastto these early
favorable observations.We examined the short- and long-
term effects of two calcium channelantagonists,verapamil
and nifedipine, in 12 patients with primarypulmonaryhy-
pertension and otherobliterative pulmonaryvascular dis-
eases, and comparedtheir effects with those of the direct-
acting vasodilator drug, hydralazine. All three drugs produced
similar degrees of pulmonaryvasodilation, but in contrast
to hydralazine, both calcium channel antagonists exerted
hemodynamically and clinically significant negative ino-
tropic effects on rightventricularfunction, which were ac-
companiedby severe adverse clinicalreactions.
Methods
Study patients. Our study groupcomprised12 consec-
utive patients with pulmonaryhypertension secondary to
obliterativepulmonaryvasculardisease. There were eight
women and four men, ranging in age from 24 to 64 years
(mean 46). The cause of pulmonaryhypertensionwas un-
known (primarypulmonaryhypertension) in eight patients;
this diagnosis was established by normal ventilation-per-
fusion scintigraphy,pulmonaryfunction tests and pulmo-
nary angiography,and was confirmed by open lung biopsy
in five patients. One patient had a history of recurrent throm-
boembolic events 5 yearsearlier, but had experienced no
recent clinical episodes. Two patients had a history of sys-
temic lupus erythematosus,but had minimal evidence for
active disease at the time of entry into the study. One 32
year old patient hadpulmonaryhypertensionsecondary to
a congenitalventricularseptal defect that had been surgically
closed at 7 years of age. One patient had been included in
a prior trial ofvasodilatortherapy in patients with pulmonary
hypertensionthat has been reported from this institution(I).
All patients had dyspnea and fatigue on minimal or mod-
erate exertion, but none had an acute respiratory or cardiac
illness at the time ofevaluation. Right heartcatheterization
had previously confirmed the presence of marked elevation
of pulmonaryartery pressure (mean pulmonary artery pres-
sure> 35 mm Hg) with nopulmonaryvasodilator response
to breathing 100% oxygen; the pulmonary capillary wedge
pressure was less than 15 mm Hg in all patients. All patients
had normal leftventricularfunction, but moderately to
markedly depressed rightventricularfunction evaluated by
contrastangiographyor gatedequilibriumscintigraphy.All
but one patient hadelectrocardiographicevidence for right
ventricularhypertrophy.Concomitanttherapy included di-
goxin in two patients, diuretic drugs in fivepatients, cor-
ticosteroids in two patients andanticoagulantagents in one;
these drugs werecontinuedin unchangeddoses throughout
the study.
Hemodynamicmeasurements. All patients were stud-
ied during a period of clinical stability. After written in-
formed consent was obtained, and withoutpremedication,
right heartcatheterizationand radial arterialcannulation
were performed with a triple lumen flow-directedcatheter
for measurementof right atrial,pulmonaryartery, pulmo-
nary capillary wedge and systemic arterialpressures.Hemo-
dynamicmeasurementswere made with zero reference level
at the midaxillary line with the patient supine. Left ven-
tricular filling pressure wasmeasuredas the mean pulmo-
nary capillary wedge pressure.Thermodilutioncardiac out-
put was determined by a bedside cardiac outputcomputer
using iced injectate. Heart rate wasderived from a contin-
uously recordedelectrocardiogram.
Drug administration.Our protocolconsistedof a min-
imum of 3 days of continuoushemodynamictesting, during
which each patient received adifferent drug on each day.
Before each drugevaluation,patients were kept at bed rest
and in a postprandial state for at least 12 hours, and the
patients'usual medications were withheld untilcompletion
of the day's hemodynamicmeasurements.On the morning
of each day, measurementof mean systemic arterial pres-
sure, heart rate, meanpulmonary artery pressure, mean
pulmonary capillary wedgepressure,mean right atrial pres-
sure and cardiac output wereperformedrepeatedly until a
stable hemodynamic control state was achieved« 10%
variation among threeconsecutivemeasurements).Each pa-
tient then receivedhydralazine, nifedipine or verapamil,
followed by administrationof the other two drugs on sub-
sequent days; nifedipine andverapamilwere administered
at least 48 hours apart to avoidcarryovereffects between
the two calcium channelantagonists.Hydralazinewas given
as 20 mg intravenously, and nifedipine as 20 mg orally.
Verapamil wasadministeredaccordingto one of two dosing
regimens: three patients received a single dose of 120 mg
orally followed by 120 mg four times daily;however, be-
cause this regimen produced adverse effects, the drug was
administered to the other nine patients as 5 mg intrave-
nously, which (if tolerated) was followed by an additional
5 mg 10 minutes later.Hemodynamic variables were re-
determinedevery 10 minutes for 30 minutes after hydral-
azine, every 30 minutes for 3 hours after each dose of oral
verapamil,every 5 minutes for 30 minutes afterintravenous
verapamil and every 30 minutes for 3 hours after nifedipine.
One patient who received verapamil first andexperienced
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an adverse drug effect declined further evaluation and did
not receive hydralazine or nifedipine.
Arterial blood gases were determined in duplicate (Ra-
diometer Copenhagen Acid-Base Laboratory ABL-2 ana-
lyzer) before theadministrationof each drug and at peak
drug effect in10 of the 12 patients receiving verapamil, in
10 of the 11 patients receiving hydralazine and in 8 of the
11 patients receiving nifedipine. None of the patients re-
ceived oxygen during the course of hemodynamic mea-
surements or during the sampling of arterial blood gases.
Exercise testing. The three patients (Cases 1 to 3) who
received verapamil orallyunderwentformal exercise testing
before and after drugadministration.After a stable hemo-
dynamic state was achieved while supine, each patient was
placed in the sitting position on a bicycle ergometer (Tenturi
ergometer,AmerecCorporation)and the pressure transducer
level was adjusted to the level of the right atrium. After
hemodynamicvariables were recorded while sitting, patients
pedaled the bicycle for 3 minutes at 150kpm/h, followed
by increments of 150 kpm/h every 3 minutes until exhaus-
tion. All hemodynamic variables were recorded continu-
ously during the period of exercise; arterial and mixed ve-
nous blood was collected for blood gas analysis before exercise
and at peak effort. When exercise testing was repeated after
short- orlong-termtreatment with verapamil, the evaluation
was performed90 minutes after drug administration in a
fashion identical to that followed during the control period,
utilizing the sametransducerpositions, work loads and end
points forexertion.
Long-termtherapy. Long-termtherapy was initiated in
five patients who tolerated short-term calcium channel
blockade and who showed favorable hemodynamic effects:
one patient received verapamil, three received nifedipine
and one received long-termcombined therapy with nifedi-
pine and hydralazine.The one patient who received vera-
pamil on along-termbasis underwent repeat hemodynamic
evaluation after 3 months and again afterII months of
continuous verapamil therapy. During bothreevaluations,
the hemodynamiceffects of verapamil were assessed at rest
and duringexercise, followed by repeat evaluation 48 hours
after drugwithdrawal.
Data analysis. Mean systemic and pulmonary artery
pressures weredeterminedby electronic filtration. Derived
hemodynamic variables were calculated according to the
following formulas:
Cardiac index (CI)= CO/body surface area (liters/min
per rrr')
Stroke volume index (SVI)= CIIHR (cc/beat perrrr')
Left ventricularstroke work index (LVSWI)= SVI x
0.0136 x (MAP - PCW) (g-m/nr')
Right ventricularstroke work index (RVSWI)= SVI x
0.0136 x (MPAP - MRAP) (g-m/rrr')
Systemic vascular resistance (SVR)= 80 x (MAP -
MRAP)/CO (dynes-s-cm- 5)
Pulmonary vascular resistance (PVR)= 80 x (MPAP
- PCW)/CO (dynes-s-cm- 5)
Total pulmonary resistance (TPR)= 80 X MPAP/CO
(dynes-s-cm- 5),
where CO denotes cardiacoutput, HR = heart rate, MAP
= mean systemic arterialpressure, PCW = pulmonary
capillary wedge pressure, MPAP= mean pulmonaryartery
pressure, MRAP= mean right atrialpressure,RV = right
ventricular and LV= left ventricular.
In the three patients undergoinghemodynamicevaluation
during exercise, maximal oxygen consumption (VOzmax,
ml of 02/kg per min) wascalculated from the product of
cardiac output (liters/min) and thedifference in the arterial-
venous oxygen contents ([ml Ozl1ooml blood] x 10). The
latter variable wascalculatedfor arterial and mixed venous
blood using the formula: O2 content (ml 021100 ml blood)
= hemoglobin concentration(g/100 ml blood) x 1.34 ml
Ozl100 ml blood x Oz saturation.
The effectsofeach drug were evaluated at its peak effect
on pulmonary and systemic vascular resistance.This was
noted 10 to 20 minutes after theadministrationof intrave-
nous hydralazine,30 to 60 minutes after oralnifedipine, 24
hours after theadministrationof three to four doses of oral
verapamil (90 minutes after drugadministration)and 5 to
10 minutes after intravenousverapamil.For each drug, these
responses werecomparedwith control values before drug
administrationby the t test for paired data. The hemody-
namic changes with each drug werecompared with the
responses seen with the other two agents by a two-way
analysis of variance procedure followed byDuncan'smul-
tiple range test todifferentiateamong mean values. The one
patient who received only verapamil was excluded from the
evaluation of comparativehemodynamic effects. Because
pulmonary capillary wedge pressures could not consistently
be obtained during exercise in anypatient, total pulmonary
resistance was used as the measure ofpulmonaryresistance
during effort. Group data wereexpressed as mean values
± standard error of the mean.
Results
Hemodynamic effects at rest.The hemodynamic re-
sponses to hydralazine,verapamil and nifedipine in theII
patients who received all three drugs are shown in Figures
I to 3.
Pulmonary vascular resistance and cardiac index. All
three drugs produced marked and similar decreases in pul-
monary vascular resistance.However, this was accom-
panied by a significant increase in cardiac index with hy-
dralazine (from 2.02 to 2.73 liters/min per m", p< 0.01),
no change in cardiac index with nifedipine (from 2.04 to
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* (hatchedbars) the administration of hydralazine (H),3.0 * 105 30 verapamil (V) and nifedipine (N) in 11 patients with
pulmonary hypertension. Theasterisks and daggers
denote significance of differences between control val-
2.4 90 24 ues and the values after the administration of each drug.~ The probability (p) values at the top ofeach paneldenote significance of the differences seen between1.8 75 18 drug treatments in the magnitude of drug-inducedchanges. The values shown are mean values± stan-dard error of the mean.1,2 60 12
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* .p <.01 '·p<.05
2.18 liters/min perrrr')and a significant decrease in cardiac
index with verapamil (from2.05 to 1.80 liters/min per m2 ,
p < 0.05). Part of the differences in the effects of these
drugs on cardiac index were the result of differences in their
effects on heart rate, which increased significantly with hy-
dralazine and nifedipine (p< 0.05), but decreased in6 of
the 11 patients receiving verapamil. When these differences
in heart rate wereconsidered,stroke volume index increased
only with hydralazine (p< 0.01) and did not change after
verapamil or nifedipine.
Pulmonary artery pressure. Because cardiac index and
stroke volume index failed to increase and pulmonary vas-
cular resistance decreased after calcium channel blockade,
mean pulmonary artery pressure decreased markedly(-16.0
± 4.3 mm Hg withverapamiland -14.5 ± 4.7 mm Hg
with nifedipine, both p < 0.01) and this reduction was
associated with a significant increase in mean right atrial
pressure (+6.2 ± 0.8 mm Hg with verapamil and+4.4
± 1.0 mm Hg with nifedipine, both p < 0.01); neither
variable changed during hydralazine administration. The
three patients with the greatest decrease in cardiac index
with calcium channel blockade(> 0.50 liter/min per m2)
had the greatest decrease in meanpulmonaryartery pressure
(> 15 mm Hg) and the greatest increase in mean right atrial
pressure(> 5 mm Hg). Rightventricularstroke work index
decreased markedly with bothcalcium channel blocking
agents (-7.0 ± 1.3 and - 4.6 ± 1.2 cc/beat per m2 with
verapamil andnifedipine, respectively, both p< 0.01), but
increased significantly with hydralazine (+ 4.1 ± 1.7 cc/beat
per m", p< 0.05) (Fig. 4).
Systemic vascular resistance. Systemic vascular resis-
tance decreased similarly withhydralazineand nifedipine
(-41 versus -34%, respectively, both p < 0.01). These
changes were significantly greater than thedecreases seen
with verapamil ( - 13%,P < 0.05). However, because car-
diac index decreasedwith verapamil,the decrease in mean
systemic arterial pressure with all three drugs was similar.
Pulmonary capillary wedge pressureincreasedsignificantly
with verapamil (+ 2.0 ± 0.5 mm Hg, p < 0.01), but not
with hydralazine or nifedipine;accordingly, left ventricular
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Figure 2. Values for mean pulmonary artery pres-
sure, pulmonary capillary wedge pressure and mean
right atrial pressure before (openbars) and after
(hatched bars) the administration of hydralazine,
verapamil and nifedipine. Format and abbreviations
as in Figure 1.
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administrationof hydralazine,verapamiland nifed-
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stroke work indexdecreased with verapamil (23.9 ± 3.2
to 18.5 ± 3.3 g-m/rrr',p < 0.01), but not with the other
two drugs.
We defined afavorableresponse to a drug as adecrease
in pulmonaryvascularresistancegreaterthan 20% that also
exceeds the correspondingdecrease in systemic resistance.
Such a response was seen in one patientreceiving hydral-
azine, five patients receiving verapamil and threepatients
receiving nifedipine;all three patientsin the last group had
also had afavorable response to verapamil.
In one patient who had a favorablehemodynamic re-
sponse to hydralazine and nifedipine when administered
alone, combined therapyproducedadditive hemodynamic
benefits (Fig. 5). With hydralazine alone, cardiac index
incteased from 2.1 to 3.4 liters/minper rrr'and pulmonary
vascular resistance decreased from 1,086 to 624dynes-scm-5;
with nifedipine alone, cardiac index increased from 2.2 to
3.2 liters/min per m2 and pulmonary vascular resistance
declined from 1,224 to 714 dynes-s-cm-5. With combined
therapywith hydralazine(600 mg daily) andnifedipine (60
mg daily) for 24 hours, cardiac index increased to 4.5 li-
ters/minper m2 andpulmonaryvascularresistancedecreased
to 499 dynes-s-cm-5.
Systemicoxygen saturation. This variabledid not change
after hydralazineor verapamil, but decreased significantly
after nifedipine (92.0 to 89.8%, p < 0.05) in our patients.
Individually, systemic oxygen saturationdecreased signif-
icantly (~ 3%) in one patient receiving hydralazine, two
patients receiving verapamil and three patients receiving
nifedipine (Fig. 6). One patientdeveloped hypoxemia with
both calcium channel antagonists.
Hemodynamiceffects duringexercise. Before therapy
with verapamil in three patients, cardiac index increased
moderately during exercise, but this was the result of a
marked increase in heart ratebecause stroke volume index
at peak effort did notchange (Table I); hence, mean sys-
temic arterialpressuredid notincreasefrom rest toexercise.
Although systemic vascular resistance decreased with ex-
ertion in eachpatient, total pulmonaryresistance increased
during exercise, and meanpulmonaryartery and mean right
HYDRALAZINE VERAPAMIL NIFEDIPINE
(\J 36 36 36E ~<,Figure4. Rightventricular(RV)strokeworkindex EIbefore(closed circles) and after(open circles) the c> 2727 27administrationof hydralazine(H), verapamil (V) x ~& 0_0and nifedipine(N). Ovals in the marginsdesignate w0 6€ :~mean values.Probability(p) values at the bottom ~ 18 -& 18 18of each paneldenotesignificanceof thedifferences :.::cr .,. o 0 .,. -&~between control values(C) and the values after the 0 0~ 0administrationof each drug. w 9 9 9 -EO:.:: ~:0cr :~:to
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Figure5. Changes in cardiac index (CI), meanpulmonaryartery
pressure (MPAP), meansystemic arterial pressure(MAP) and
pulmonaryvascular resistance (PVR) in a patient whoreceived
individualand combinedtherapy withydralazineandnifedipine.
Single doses of hydralazineand nifedipine were initially admin-
isteredintravenously(IV) and orally (PO),respectively, followed
by oralhydralazinetherapy (singledose of 100J11g and then daily
doses of 300 mg and 600 mg). While a daily dose of 600 rng of
hydralazinewas being administered,oral nifedipine was added,
first as a single dose of 20 mg and then as 60 mg daily.
atrialpressuresincreaseddramatically.These hemodynamic
changes were associated with little change in systemic ox-
ygen saturationin two patients, but with adecrease in the
third patient (from 91 to 83%), who experienced syncope
at peakeffort. Oxygen consumptionincreasedtwo- to three-
fold duringexercise in all three patients, but maximal ox-
ygen consumptionwas severely limitedin all « 10 ml/kg
per min).
After 48 hours of verapamil therapy, two of these three
patients showed notable increases in stroke volume index
at peakeffortcomparedwith preverapamilexercise values.
Exercise-inducedincreases in heart rate, mean pulmonary
artery pressure and total pulmonary resistance were also
attenuatedby verapamil(Table 1). Exercise-relatedchanges
in systemic vascular resistance were not altered. Despite
these favorableacute responses, exercise durationand max-
imal oxygen consumptionwere not significantly increased
by short-termverapamiltherapy. The third patientexperi-
enced syncope earlier duringexercise after verapamilthan
before treatment,and hemodynamicvariablescould not be
completely assessed.
Clinical responses (Table2). No patient experienced
symptomaticimprovementaftershort-termvasodilatorther-
apy, and 11patientshad adverse reactions to one or more
of the agentsevaluatedduring thecourseof short- and long-
term treatment.
Hydralazine. Three patientshad immediate adverse re-
actions to hydralazine.Two patients experiencedhypoten-
sion anddizziness, one of whom requiredintravenouspres-
sor therapy for circulatory support. The third patient
experienced chest pain, dyspnea and hypoxemia, which were
alleviated with supplementaloxygen.
Verapamil. Six patientsexperiencedimmediateside ef-
fects with verapamil.These cohsistedof a junctionalrhythm
in one patient(which produceda markeddecreasein cardiac
index), dyspnea and hypoxemia in two patients(associated
with decreases in systemic oxygen saturationto below 90%
in both) and chest pain, dyspnea and hypotension in one
patient. These four patientsrespondedto withdrawalof the
drug and supplementaloxygen. In the two remainingpa-
tients who received verapamil(5 mg intravenouslyin one
and 10 mg intravenouslyin the other), drug administration
was followed by the rapiddevelopmentof cardiogenicshock
characterized by severe dyspnea, profound hypotension, loss
of consciousnessand finallycardiacarrest(precededby third
degree heartblock in one patient);cardiac index decreased
markedly in association with a dramatic increase in mean
right atrialpressure.Both patientsrespondedrapidlyto car-
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Table 1. IndividualHemodynamicResponses in Three Patients to Verapamil at Rest and During Exercise
MAP HR PA RA CI SVI SVR TPR A02% V02 ExD
Patient I
C 79 103 50 4 2,14 20,8 1,667 1,111 94 2.8
Ex 77 133 77 17 2.39 18,0 1,197 1,536 94 9,2 375
V-48h 73 73 32 9 1.91 26.2 1,595 798 93
Ex-48h 85 106 58 17 3.17 29.9 1,021 871 92 10.3 382
V-3mo 79 79 44 9 1.93 24.4 1,728 1,086 93
Ex-3mo 85 120 73 26 2,83 23.6 994 1,229 91 9.9 470
V-off 85 99 59 3 2.14 21.6 1,827 1,315 94
Ex-off 94 142 86 18 2.10 14.8 1,722 1,949 93 9.2 390
V-limo 80 78 46 21 1.73 22.2 1,622 1,265 94
Ex-lImo 60 106 54 34 2.04 19.2 606 1,259 94 9.0 330
V-off 80 99 63 8 2.17 22.0 1,578 1,381 95
Ex-off 78 128 82 32 2,13 16.6 1,031 1,838 95 8.9 255
Patient 2
C 82 73 54 10 2.23 30.5 1,371 1,162 92 2.7
Ex 76 126 81 27 2.49 19.8 838 1,385 91 8.7 370
V-48h 64 56* 39 13 1.47 26.3 1,478 1,130 91
Ex-48!J 67 72 57 20 2.25 31.3 851 1,078 92 8.5 350
Patient 3
C 70 93 88 6 1.54 16,6 2,349 3,229 91 3.8
Ex 80 133 107 18 2.23 16.8 1,565 2,700 83 6.7 285
V-48h 66 89 77 6 1.78 20.0 1,897 2,435 89
Ex-48h 78 100 84 20 nlo nlo nlo n/o 84 n/o 45
*The occurrenceof junctionalrhythm, A02% = systemic arterial oxygen saturation(%); C = control; CI = cardiac index (liters/min per rrr'); Ex
= peak exercise; ExD = exercise duration (seconds); HR= heart rate (beats/min); MAP= mean arterial pressure (mm Hg); n/o= not obtained; PA
= mean pulmonary artery pressure (mm Hg); RA= mean right atrial pressure (mm Hg); SVI= stroke volume index (cc/beat per rrr'); SVR= systemic
vascular resistance (dynes-s-cmr "); TPR = total pulmonary resistance (dynes-s-cmr '): V02 = oxygen consumption (ml 02/kg per min); V-48h= after
48 hours of verapamil therapy; V-3mo= after 3 months of verapamil therapy;V-limo = after II months of verapamil therapy; V-off= 48 hours
after withdrawal of verapamil.
diac resuscitative efforts that included intravenous pressors
and calcium chloride.
Nifedipine. Four patients had immediate adverse effects
with nifedipine. Two patients experienced the acute onset
of dyspnea and hypoxemia (associated with decreases in
systemic oxygen saturation to below 90% in both); one
patient responded to drug withdrawal and supplemental ox-
ygen, but the other required intravenous calcium chloride
to reverse the effects of nifedipine and died 36 hours after
nifedipine administration despite withdrawal of the drug.
One patient developed severe dyspnea, chest pain, palpi-
tation and hypotension, which lessened without specific
Table 2. Adverse Clinical Reactions Noted During the Trial
Hydralazine Verapamil Nifedipine
Symptomatic hypotension
Dizziness only 2 0 0
Dyspnea or chest pain, or both 0 I I
Cardiogenic shock 0 2 I
Symptomatic hypoxemia
Dyspnea or chest pain, or both 2 2
Othercardiovascularreactions
Junctional rhythm 0 0
Worsening right heart failure 0 3
Noncardiac adverse effects
Systemic lupus erythematosus I 0 0
Total 4 7 6
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therapy . The fourth patientexperiencedsevere hypotension ,
loss of consciousnessandcardiogenicshock30 minutes after
nifedipineadministrationwhich was accompaniedby a marked
decrease in cardiac index and an increase in mean right
atrial pressure; theconditionof this patient improved grad-
ually after treatment with intravenous pressors and calcium
chloride.
During this study, theoccurrenceof adverse hemody-
namic and clinical events during theadministrationof one
calcium channel antagonist could not be predicted from a
patient'sprevious experience with the other.
Clinical effects of long-termtherapy. Long-term ther-
apy was instituted in five patients: verapamil(480 mg daily)
in one, nifedipine(60 mg daily) alone in three andcombined
nifedipine-hydralazine(60 and 600 mg, respectively, daily)
in one . The three patients who received nifedipine alone
developed increasing jugular venous distension, hepato-
megaly or ascites, or both, and pretibial edema after several
weeks of treatment with the drug; all three patients had
shown marked increases in mean right atrial pressure during
administration of nifedipine during the period of invasive
hemodynamictesting . None of these patients showed clin-
ical improvement,and evidence for right heart failure sub-
sided in the two patients in whom nifedipine was withdrawn .
The one patient with primarypulmonary hypertension who
received combined treatment with nifedipine and hydrala-
zine improved clinically during a follow-up period of I year;
hydralazine wasdiscontinuedafter 8 months because of the
developmentof drug-inducedlupus erythematosus.
The one patient who received long-term treatment with
verapamil (Case 1, Table 1)experienced ameliorationof
dyspnea and fatigue early in the course of treatment with
the drug; after 3 months of therapy, exercise duration had
increased from375 to 470 seconds in association with an
increase in maximal work load achieved from300 to 450
kpm/h. Repeat hemodynamic assessment after 3 months
showed sustained effects of verapamil with continued en-
hancementof exercise-relatedincreases in cardiac index and
attenuation ofexercise-inducedincreases in mean pulmo-
nary artery pressure and total pulmonary resistance; with-
drawal of verapamil produced a loss of thesehemodynamic
benefits. However , despite these favorableresponses, max-
imal oxygen consumption was not significantly increased
during verapamiltherapy, and mean right atrial pressure
increased from 4 to 9 mm Hg after 3 months of treatment
and decreased to 3 mm Hg when the drug was withdrawn.
Long-term verapamil therapy was reinstituted , but after 8
months of treatment, the patient'sclinical state began to
deteriorate and he no longer feltimprovementwith the drug;
exercise durationdecreasedto 330 seconds and he developed
pretibial edema despite increasing doses of diuretic drugs .
Repeat right heartcatheterizationafter 11 months of treat-
ment showed continued effects of verapamil, but cardiac
index haddecreasedsignificantly and mean right atrial pres-
sure had increased markedly to21 mm Hg; at this time ,
exertion was accompan ied by markedecreasesin systemic
blood pressure .Withdrawalof verapamil resulted in an in-
crease in cardiac index , a decrease in mean right atrial
pressure to 8 mm Hg,disappearanceof exercise-related
hypotension and gradual resolution of clinical evidence of
right heart failure. Althoughexercise durationdecreasedon
withdrawal of the drug, maximal oxygenconsumptiondid
not decrease and the patient did notexperience subjective
worsening of his symptoms .
Discussion
Although thepathophysiologicfactors that underlie the
developmentof pulmonaryhypertensionremain unknown,
the obliterativevascular lesions thatcharacterizethis dis-
order have long been thought to occur secondary to abnormal
pulmonary vasoconstriction (2,32,33 ). Consequently, a
number of vasodilatordrugs have been administered to these
patients in an attempt to attenuate the vasoconstrictive com-
ponents of the disease and forestall thedevelopment of
irreversible vascular sequelae (10).Unfortunately, although
early reports suggested that a variety of vasodilator agents
could produce highly favorable effects in some patients with
pulmonary hypertension, subsequentexperience indicated
that these drugs failed toconsistentlyproducehemodynamic
and clinical benefits and had manydisadvantages. Some
drugs proved effective only whenadministered intrave-
nously or had a short duration of action(2- 4 ,6). Others had
potent positive inotropic andchronotropiceffects in addition
to their pulmonaryvasodilatoractions and could increase
pulmonary artery pressures(7-10). All vasodilatortherapy
carried the risk of producingprofoundhypotension if the
magnitude of systemic vasodilation exceeded the corre-
sponding decrease in pulmonary vascular resistance (l ,10).
This was particularlytrue of drugs that exertedpreferential
effect on the systemiccirculation( I) .
Rationalefor calcium channel antagonistsin pulmo-
naryhypertension. In view of these importantlimitations,
the use of calcium channel antagonists hasenormous the-
oretical appeal in the treatment of pulmonaryh pertensive
states. Verapamil and nifedipine are effective orally and
have a prolonged duration of action.Furthermore,these
drugs areparticularlyactive in vasospastic states(34) and
exert direct dilator effects on the pulmonarycirculation
(35,36). In experimental preparations , calcium channel
blockade inhibits the pulmonaryvasoconstrictorresponse to
acute hypoxia (18,19,37-39) and reduces the severity of
pulmonaryhypertensionand secondary rightventricularhy-
pertrophyinduced by chronic hypoxia(40,41). Preliminary
clinical trials(20-22,42) have indicated that calcium chan-
nel antagonists may be useful in the treatment of patients
with hypoxic pulmonaryvasoconstriction.Hypoxia appears
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to inducepulmonaryhypertensionby interruptingthe ability
of arterial smooth muscle cells to maintain atransmembrane
ionic gradient.The resultantincrease incytoplasmiccalcium
levels leads to pulmonaryarteriolarconstriction (43) that
can be blocked by calcium channel antagonists.
Experience with calcium channel antagonists in pri-
mary pulmonary hypertension. Reports of the benefits of
calcium channel blockade in patients with hypoxic pul-
monary hypertensionhave led to the application of these
drugs to thetreatmentof patients with primarypulmonary
hypertension.In a series of case studies(23-31), nifedipine
increased cardiac output and decreased pulmonaryartery
pressure andpulmonaryvascularresistanceboth at rest and
during exercise in selected patients with this disorder; these
hemodynamiceffects were sustainedfor 2 to 6 months and
were associatedwith animprovementin exercise tolerance.
Benefits with the use ofdiltiazem and verapamil have also
been reported(27,28), Few adverse cardiovasculareffects
were noted in theseinvestigations, which is surprising be-
cause all three drugs blocktransmembranecalcium transport
in cardiac muscle cells and can exert direct negative ino-
tropic effects (35,44,45), especially in patients in whom
right ventricularcontractilitymay have beencompromised
by chronic pressureoverload. The absence of such adverse
reactionsmay reflect the fact that few of these reports eval-
uated theeffects of calcium channel blockade on right ven-
tricularfunction by assessing right ventricularfilling pres-
sures orejection fraction.
Findings of the present study. The results of this study
are in markedcontrastto previous favorable observations
of calcium channel blockade in pulmonary hypertensive states.
Althoughboth nifedipineand verapamilreducedpulmonary
vascularresistance significantly and to a similar degree in
our patients, cardiac index and stroke volume index failed
to increase despite the decrease in impedanceto right ven-
tricularejection. This failure occurredbecause right ven-
tricularperformancedeterioratedmarkedlyduringtreatment
with both calcium channel antagonists, as reflected by the
substantialdecrease in rightventricularstroke work and the
marked increase in right ventricularfilling pressure that
followed administrationof these drugs. These responses are
in contrastto the effects of hydralazine, which increased
cardiac index, stroke volume index and rightventricular
stroke work index in these samepatients without signifi-
cantly affecting mean right atrialpressure. These unfavor-
able hemodynamiceffects of verapamiland nifedipinewere
accompanied by severe adverse clinical events, including
the precipitation of severe hypotension and cardiogenic shock
duringshort-termtherapyand rightventricularfailure during
long-termtreatment.
The pathophysiologic mechanisms that underlie the re-
duction inpulmonaryartery pressures after calcium channel
blockade require further comment. We would expect that
the decrease inpulmonaryvascular resistance that occurs
after the administrationof an arterial vasodilatordrug in
patients withpulmonaryhypertensionwould be matchedby
an increase in rightventricularoutput, so that little change
in meanpulmonaryartery pressure would beobserved(13).
A similar hemodynamic response is seen inpatients with
left heart failure treated with arterialvasodilatingagents, in
whom therapy produces little change insystemic pressures
because left ventricularoutput increases to offset the de-
crease insystemic resistance(46,47). This conceptexplains
why diazoxide andhydralazineproducelittle change in pul-
monary artery pressures inpulmonaryhypertensive states
(I, 13,14). In contrast, although nifedipine and verapamil
exert arterialvasodilatoractions similarto those of hydral-
azine (48), both drugsreduce mean pulmonaryartery pres-
sures substantiallyin patients withpulmonaryhypertension
(23-27); this can only beexplained by postulatingan im-
provementin pulmonaryartery compliance (49) or, more
likely, a reduction in pulmonaryblood flow (13). Although
the latter could result from adecrease in venous return to
the right side of the heart (as occurs inpatientswith primary
pulmonary hypertension after nitroglycerin [50D, neither
nifedipine nor verapamil is known to exert directvenodilator
effects in human subjects (48).Rather, our data indicate
that the decrease inpulmonaryartery pressures and pul-
monary blood flow seen aftercalcium channel blockade
likely results from adepressanteffect exertedby these drugs
on rightventricularfunction, because right heart filling pres-
sures increased in our patients and thetranspulmonarydriv-
ing pressure (meanpulmonaryartery pressure-pulmonary
wedge pressuregradient)decreased(20). In this regard, in
patients withpulmonaryhypertensionin whom nifedipine
failed to reduce mean pulmonary artery pressures, right
ventricularfunction improvedrather thandeteriorated(30).
The decrease in pulmonaryarterypressuresthat follows the
administrationof drugs with negativeinotropic effects is
opposite but analogous to the exacerbationsof pulmonary
hypertensionseen aftertreatmentwith drugs that have pos-
itive inotropicactions (forexample. isoproterenol)(7-10).
Comparative cardiodepressant effects of verapamil
and nifedipine. Nifedipine and verapamilexerted similar
detrimentaleffects on rightventricularperformancein our
patients with severepulmonaryhypertension.Althoughthis
is consistent with the known abilityof both drugs to block
transmembranecalciumtransport in cardiac muscle and thus
depress myocardialcontractility(35,44,45), it has long been
thought that the negative inotropic effects of nifedipine in
human beings arenegligible, largely because its potent vas-
odilatoreffects can offset any directdepressanteffects ex-
erted on themyocardium(51). However, this may not be
true in patients with poor leftventricularfunction, who may
show worsening of heart failure duringtreatmentwith both
verapamil andnifedipine(52-54); our observationsprovide
the firstevidence that these drugs may exertimportantneg-
ative inotropiceffects on the right side of the heart as well.
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In pulmonary hypertensive states , the right ventricle , al-
ready depressed by the effects of chronic pressure overload ,
may be particularlysensitive to the effects of calcium chan-
nel blockade. In addition, the degree of pulmonary vaso-
dilation may be limited byobliterativevascular disease, and
thus may be insufficient to offset even a modest direct car-
diodepressanteffect of these drugs . The only significant
difference that we observed between verapamil and nife-
dipine in our patients was in their respective effects onleft
ventricularperformance. Whereas verapamil produced a
downward shift in the leftventricularfunction curve (left
ventricularstroke work index decreased and leftventricular
filling pressureincreased), neither variable was altered by
nifedipine, possibly because nifedipine exerted greatersys-
temic vasodilatoractions than did verapamil.
The deterioration of right ventricular performance seen
in ourpatients after calcium channelblockade may not have
been solely the result of a negative inotropic effect of ni-
fedipine andverapamil,but may have been the consequence
of ischemic rightventriculardysfunction resulting from a
decrease in perfusion pressure to the right coronary artery
(55) . This sequence of events may explain the refractory
hypotension seen in some patients with pulmonary hyper-
tension after therapy with systemic vasodilators. Blood flow
to the hypertrophiedright ventricle in patients with pul-
monaryhypertensionis likely to be marginal (56); any de-
crease in systemic blood pressure mayexacerbateischemia
and thereby worsen rightventricularfailure. However, isch-
emic dysfunction appeared to be an unlikely explanation for
our findings since mean systemic blood pressure decreased
to a similar extent with all threevasodilatordrugs evaluated
in our study, yetdeteriorationof right ventricular perform-
ance was seen only after calcium channel blockade. Fur-
thermore,of the three agents used, hydralazine was most
likely to exacerbateischemia because of its predilection to
elicit reflex tachycardia,yet it improved right ventricular
function in our patients .
Mechanism underlyingthe development of systemic
arterial hypoxemia. An acute exacerbation of systemic
hypoxemia was seen six times during the course of the
present trial. In all but one case , this occurred after calcium
channel blockade. Theprecipitationof hypoxemia in pa-
tients with pulmonaryhypertensionis well known and has
been observed after theadministrationof tolazoline, hy-
dralazine andnitroglycerin(1,57,58). A similar phenome-
non has been reported (20) withnifedipine, but only in
patients with hypoxic pulmonaryhypertension.Regardless
of the underlying cause of thepulmonaryhypertensivestate,
hypoxemia appears to result from venousadmixturebecause
the pulmonary vessels most likely to bepharmacologically
responsive tovasodilatordrugs are those that maintain nor-
mal ventilation-perfusionrelations in patients with obliter-
ative pulmonary vascular disorders(l ,59,60). Normally,
such admixture is rarely of clinicalimportance,because if
cardiac output increases as a result of drug therapy, oxygen
transport to the tissues may paradoxically be enhanced
(20,59) . Furthermore,any drug-inducedincrease in cardiac
output will serve to increase mixed venous oxygen content ,
a majordeterminantof systemic oxygen saturation in pa-
tients with obliterative pulmonary vascular disorders(59-61) ,
and, thereby, prevent significant systemic oxygen desatu-
ration (l ,13). On the other hand, should an increase in
cardiac output fail toaccompanyvasodilatortherapy,clin-
ically important systemic hypoxemia may be seen (1,58).
This may explain the occurrence of serious hypoxemic events
after calcium channel blockade in thepresentstudy, since
little improvement in cardiac output accompanied drug-
induced pulmonary vasodilation .
Precautions and limitations. Our results need to be
interpreted in the context of certainprecautionsand limi-
tations. We administered fixed doses of all threevasodilator
drugs to the patients in our study based on the doses that
have been found to be effective for thetreatmentof angina
pectoris andsupraventriculartachyarrhythmia(62,63). Our
results may have differed (and the negative inotropic effects
of these calcium channelantagonists may have been less
marked) if lower doses of the drugs had been utilized. How-
ever , the doses that we used were similar to orsmallerthan
those chosen by previousinvestigations(23-31) in patients
with pulmonaryhypertension,and the ability of lower doses
to produce significant pulmonaryvasodilationis uncertain .
More important,our observations were made in patients
with advanced pulmonaryhypertension,in whom the pul-
monary vasculaturemay be less responsive tovasodilator
therapy and the magnitude of rightventriculardysfunction
may be greater than in patients treated earlier in the course
of the disease (15). To support thishypothesis, we noted
the most favorable effects of calcium channelblockade in
the two patients in our study who had a mean right atrial
pressure of less than 5 mm Hg before drugadministration.
The condition of both patients improved during long-term
treatment , one with verapamil and the other withcombined
therapy of nifedipine andhydralazine,and in neither patient
did drug therapy produce notabledepressanteffects on the
right ventricle .Therefore, calcium channelblockade may
be beneficial in patients with primary pulmonary hyperten-
sion if administered before severe right ventricular dys-
function has occurred.Whetherthis explains the more fa-
vorable effects of these drugs seen in previous studies(23-31)
remains unclear since rightventricularfilling pressures in
those patients were not measured .
Conclusion. Although calcium channel antagonists can
exert preferentialdilating effects on the pulmonary circu-
lation in patients with pulmonaryhypertension,these agents
may also exertimportantdirectcardiodepressanteffects on
rightventricularfunction, which can result in severe adverse
clinical events. Such reactions may not occur in patients
with less advanced pulmonary vascular obliteration or right
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ventriculardysfunction. Thus, patients with pulmonary hy-
pertensionwho may benefit from calcium channel blockade
need to be carefully selected. Therapy should be initiated
under controlledconditions and guided by invasive hemo-
dynamic measurements.
We are indebted to the nurses of the Ames and Rose Cardiac Care Units
for the excellent care they provided the patients in this study.
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